---
title: "Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284868671.md"
description: "Seaport Therapeutics, Inc. has priced its upsized IPO of 14.16 million shares at $18 each, raising approximately $254.9 million. The shares will trade on the Nasdaq under the ticker \"SPTX\" starting May 1, 2026, with the offering closing on May 4, 2026. Underwriters have a 30-day option to purchase an additional 2.12 million shares, with Goldman Sachs, J.P. Morgan, and others as joint book-running managers."
datetime: "2026-05-01T05:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284868671.md)
  - [en](https://longbridge.com/en/news/284868671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284868671.md)
generator: "portal-rs"
---

# Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each

Add  as your preferred news source on Google

 Add Now

Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. 

The company is expected to raise about $254.9 million in gross proceeds from the offering. It has also granted underwriters a 30-day option to purchase an additional 2.12 million shares. 

The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker "SPTX", with the offering expected to close on May 4, 2026. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel are serving as joint book-running managers for the deal. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**